<DOC>
	<DOCNO>NCT01933711</DOCNO>
	<brief_summary>Clinical pharmacokinetic data suggest effect rituximab could improve prolonged exposure drug . To test hypothesis perform prospective randomize trial rituximab maintenance therapy versus observation patient ( pt ) aggressive CD20+ B-cell lymphoma mantle cell lymphoma .</brief_summary>
	<brief_title>Rituximab Maintenance Therapy Aggressive CD20 ( Cluster Differentiation Antigen 20 ) Positive Lymphoma Mantle Cell Lymphoma</brief_title>
	<detailed_description>After completion standard treatment , pt aggressive CD20+ B-cell lymphoma mantle cell lymphoma randomize either observation maintenance therapy rituximab ( 375 mg/m2 ) administer every 3 month 2 year . Both pt first line therapy pt relapse treatment include study . Pts aggressive lymphoma enrol achieve complete response ( CR ) initial treatment . Pts aggressive lymphoma residual tumor mass underwent positron emission tomography ( PET ) qualify randomization examination show sign tumor activity . Pts mantle cell lymphoma eligible study least partial response ( PR ) achieve . Primary endpoint study progression free survival ( PFS ) , secondary endpoint time progression ( TTP ) , overall survival ( OS ) response treatment . Differences PFS OS analyse use logrank test proportional hazard model Cox . TTP analyze use compete risk model death compete event .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>aggressive Bcell lymphoma mantle cell lymphoma CR ( complete remission ) oder CRu ( complete remission unconfirmed ) previous therapy PR ( partial remission ) PET negative minimal age 18 year CD20+ expression tumor cell effective contraception Karnofsky status &gt; 60 write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>CD20+ aggressive lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>rituximab</keyword>
	<keyword>maintenance</keyword>
</DOC>